Candel Therapeutics Inc (NASDAQ:CADL) does about 988.78K shares in volume on a normal day but saw 995524 shares change hands in the recent trading day. The company now has a market cap of 288.09M USD. Its current market price is $5.75, marking an increase of 2.86% compared to the previous close of $5.59. The 52 week high reached by this stock is $14.60 whilst the lowest price level in 52 weeks is $3.79.
The consensus objective for the share price is $21.00, suggesting that the stock has a potential upside of 72.62% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 20, 2025 when Citigroup initiated the stock to “Buy” and issued a price target of $25. BofA Securities initiated its price target at $15.
The current price level is 7.46%, 7.26%, and -11.51% away from its SMA20, SMA50, and SMA200 respectively, with the CADL price moving below the 50-day SMA on current market day. Candel Therapeutics Inc (CADL) stock is up 2.68% over the week and 8.90% over the past month. Its price is -33.76% year-to-date and -33.29% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.17 and -0.53 for whole year.
To reach the target analysts have set, the stock logically needs to grow 72.62 percent from here.
Outstanding shares total 49.25M with insiders holding 20.83% of the shares and institutional holders owning 42.64% of the company’s common stock. The company has a return on investment of -52.19% and return on equity of -98.14%. The beta has a value of -0.87. Price to book ratio is 3.79.
